Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2256-2261

  Valade, Elodie ^a,b   Tréluyer, Jean Marc ^a,b,c,d   Bouazza, Naïm ^b,c   Ghosn, Jade ^a,e   Foissac, Frantz ^b,c   Benaboud, Sihem ^b,c,d   Fauchet, Floris ^a,b   Viard, Jean Paul ^a,e   Urien, Saïk ^a,b,c   Hirt, Déborah ^a,b,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

^d Service de Pharmacologie Clinique Hôpital Cochin Groupe Hospitalier Paris Centre ^*  (France)

^e HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR DISOPROXIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; PRIORITY JOURNAL; SIMULATION; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84896977394     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02058-13     Document Type: Article

References (20)

1. World Health Organization. 2010. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who. int/publications/2010/9789241599764-eng.pdf?ua=1.
2. Zong J, Chittick GE, Wang LH, Hui J, Begley JA, Blum MR. 2007. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J. Clin. Pharmacol. 47:877-889. http://dx.doi.org/10.1177/0091270007300808.
3. Blum MR, Chittick GE, Begley JA, Zong J. 2007. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J. Clin. Pharmacol. 47:751-759. http://dx.doi.org/10.1177/0091270007300951. (Pubitemid 46800418)
4. Chittick GE, Zong J, Begley JA, Alianti JR, Sorbel JJ, Blum MR. 2008. Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Int. J. Clin. Pharmacol. Ther. 46:627-636. http://dx.doi.org/10.5414/CPP46627.
5. Gilead Sciences. 2012. Emtriva prescribing information. Gilead Sciences, Foster City, CA. http://www.gilead.com/pdf/emtriva-pi.pdf.
6. Wang LH, Begley J, St. Claire RL, III, Harris J, Wakeford C, Rousseau FS. 2004. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res. Hum. Retroviruses 20:1173-1182. http://dx.doi.org/10.1089/aid.2004.20.1173. (Pubitemid 39557868)
7. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
8. Le Saux T, Chhun S, Rey E, Launay O, Weiss L, Viard JP, Pons G, Jullien V. 2008. Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 865:81-90. http://dx.doi.org/10.1016/j.jchromb.2008.02.008.
9. Lavielle M, Mentré F. 2007. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J. Pharmacokinet. Pharmacodyn. 34:229-249. http://dx.doi.org/10.1007/ s10928-006-9043-z. (Pubitemid 46536259)
10. Hirt D, Pruvost A, Ekouévi DK, Urien S, Arrivé E, Kone M, Nerrienet E, Nyati M, Gray G, Kruy LS, Blanche S, Dabis F, Tréluyer JM. 2011. Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2). Antimicrob. Agents Chemother. 55:2953-2960. http://dx.doi.org/10.1128/AAC.01376-10.
11. Hirt D, Urien S, Rey E, Arrivé E, Ekouévi DK, Coffié P, Leang SK, Lalsab S, Avit D, Nerrienet E, McIntyre J, Blanche S, Dabis F, Tréluyer JM. 2009. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob. Agents Chemother. 53:1067-1073. http://dx.doi.org/10.1128/AAC.00860- 08.
12. Anderson GD. 2005. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 44:989-1008. http://dx.doi.org/10.2165/00003088-200544100-00001. (Pubitemid 41356388)
13. Wijnand HP. 1988. Pharmacokinetic model equations for the one- and two-compartment models with first-order processes in which the absorption and exponential elimination or distribution rate constants are equal. J. Pharmacokinet. Biopharm. 16:109-128. http://dx.doi.org/10.1007/BF01061864.
14. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13: 143-151. http://dx.doi.org/10.1208/s12248-011- 9255-z.
15. Comets E, Brendel K, Mentré F. 2008. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput. Methods Programs Biomed. 90:154-166. http://dx.doi.org/10.1016/j.cmpb.2007.12.002.
16. Ihaka R, Gentleman R. 1996. R: a language for data analysis and graphics. J. Comput. Graph. Stat. 5:299-314. http://dx.doi.org/10.2307/1390807.
17. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504. http://dx.doi.org/10.1023/A:1012299115260. (Pubitemid 33151426)
18. Jullien V, Tréluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, Lillo-Le Louet A, Lescoat A, Dupin N, Salmon D, Pons G, Urien S. 2005. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob. Agents Chemother. 49:3361-3366. http://dx.doi.org/10.1128/AAC.49.8.3361-3366. 2005. (Pubitemid 41060583)
19. Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F. 2002. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob. Agents Chemother. 46:1734-1740. http://dx.doi.org/10.1128/AAC.46.6.1734-1740.2002. (Pubitemid 34535190)
20. Rousseau FS, Kahn JO, Thompson M, Mildvan D, Shepp D, Sommadossi JP, Delehanty J, Simpson JN, Wang LH, Quinn JB, Wakeford C, van der Horst C. 2001. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J. Antimicrob. Chemother. 48:507-513. http://dx.doi.org/10.1093/jac/48.4.507. (Pubitemid 33040691)